Cargando…

Cisplatin in breast cancer.

Detalles Bibliográficos
Autores principales:	Willemse, P., Sleijfer, D. T., Mulder, N. H., de Vries, E. G.
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1993
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968245/ https://www.ncbi.nlm.nih.gov/pubmed/8439514

Ejemplares similares

Cardiotoxicity from intensive chemotherapy combined with radiotherapy in breast cancer.
por: de Graaf, H., et al.
Publicado: (1997)

Dacarbazine (DTIC) and human recombinant interferon alpha 2a (Roferon) in the treatment of disseminated malignant melanoma.
por: Mulder, N. H., et al.
Publicado: (1990)

Dacarbazine (DTIC), human recombinant interferon alpha 2a (Roferon) and 5-fluorouracil for disseminated malignant melanoma.
por: Mulder, N. H., et al.
Publicado: (1992)

A phase II and pharmacokinetic study with oral piritrexim for metastatic breast cancer.
por: de Vries, E. G., et al.
Publicado: (1993)

Carboplatin- and cisplatin-induced potentiation of moderate-dose radiation cytotoxicity in human lung cancer cell lines.
por: Groen, H. J., et al.
Publicado: (1995)

Dacarbazine (DTIC)-based chemotherapy or chemoimmunotherapy of patients with disseminated malignant melanoma.
por: Mulder, N. H., et al.
Publicado: (1994)

Treatment of advanced seminoma with cyclophosphamide, vincristine and carboplatin on an outpatient basis.
por: Sleijfer, S., et al.
Publicado: (1996)

A phase I study of 1,2-diamminomethyl-cyclobutane-platinum (II)-lactate (D-19466; lobaplatin) administered daily for 5 days.
por: Gietema, J. A., et al.
Publicado: (1993)

Recombinant interferon alpha-2b in patients with metastatic apudomas: effect on tumours and tumour markers.
por: Biesma, B., et al.
Publicado: (1992)

Randomized comparison of etoposide pharmacokinetics after oral etoposide phosphate and oral etoposide.
por: de Jong, R. S., et al.
Publicado: (1997)

The role of glutathione in resistance to cisplatin in a human small cell lung cancer cell line.
por: Meijer, C., et al.
Publicado: (1990)

Pharmacokinetics of carboplatin at a dose of 750 mg m-2 divided over three consecutive days.
por: Mulder, P. O., et al.
Publicado: (1990)

Paclitaxel, ifosfamide and cisplatin with granulocyte colony-stimulating factor or recombinant human interleukin 3 and granulocyte colony-stimulating factor in ovarian cancer: a feasibility study.
por: Veldhuis, G. J., et al.
Publicado: (1997)

Phase I and pharmacokinetic study of the topoisomerase II catalytic inhibitor fostriecin
por: Jong, R S de, et al.
Publicado: (1999)

Guideline adherence for early breast cancer before and after introduction of the sentinel node biopsy
por: Schaapveld, M, et al.
Publicado: (2005)

Phase II and pharmacokinetic study of lobaplatin in patients with relapsed ovarian cancer.
por: Gietema, J. A., et al.
Publicado: (1995)

The formation and removal of cisplatin (CDDP) induced DNA adducts in a CDDP sensitive and resistant human small cell lung carcinoma (HSCLC) cell line.
por: Hospers, G. A., et al.
Publicado: (1990)

Carbonic anhydrase IX expression is more predictive than prognostic in breast cancer
por: Span, P N, et al.
Publicado: (2007)

Immunocytochemical analysis of cisplatin-induced platinum-DNA adducts with double-fluorescence video microscopy.
por: Meijer, C., et al.
Publicado: (1997)

Prospective Evaluation of a Circulating Tumor Cell Sensitivity Profile to Predict Response to Cisplatin Chemotherapy in Metastatic Breast Cancer Patients
por: de Kruijff, I. E., et al.
Publicado: (2021)

Feasibility of a dose-intensive CMF regimen with granulocyte colony-stimulating factor as adjuvant therapy in premenopausal patients with node-positive breast cancer
por: Bos, A M E, et al.
Publicado: (2000)

Ovarian cysts in women receiving tamoxifen for breast cancer
por: Mourits, M J E, et al.
Publicado: (1999)

Cellular basis for differential sensitivity to cisplatin in human germ cell tumour and colon carcinoma cell lines.
por: Sark, M. W., et al.
Publicado: (1995)

Acute and cumulative effects of carboplatin on renal function.
por: Sleijfer, D. T., et al.
Publicado: (1989)

Modeling of Cisplatin-Induced Signaling Dynamics in Triple-Negative Breast Cancer Cells Reveals Mediators of Sensitivity
por: Heijink, Anne Margriet, et al.
Publicado: (2019)

Mechanism of hyperthermic potentiation of cisplatin action in cisplatin-sensitive and -resistant tumour cells.
por: Hettinga, J. V., et al.
Publicado: (1997)

Decrease in pulmonary function during bleomycin-containing combination chemotherapy for testicular cancer: not only a bleomycin effect.
por: Sleijfer, S., et al.
Publicado: (1995)

Evaluation of sub-acute changes in cardiac function after cisplatin-based combination chemotherapy for testicular cancer
por: Altena, R, et al.
Publicado: (2009)

(89)Zr-trastuzumab PET supports clinical decision making in breast cancer patients, when HER2 status cannot be determined by standard work up
por: Bensch, Frederike, et al.
Publicado: (2018)

UBQLN4 promotes STING proteasomal degradation during cisplatin‐induced DNA damage in triple‐negative breast cancer
por: Shoji, Yoshiaki, et al.
Publicado: (2022)

Cost effectiveness of concurrent gemcitabine and cisplatin and radiation followed by adjuvant gemcitabine and cisplatin in stages IIB–IVA cervical cancer
por: Rajan, Narayan, et al.
Publicado: (2014)

The role of cisplatin alternative regimens with radiotherapy in cervical cancer
por: Chen, Yi-Ju Amy, et al.
Publicado: (2014)

LHRH analogues and breast cancer.
por: Korkut, E., et al.
Publicado: (1991)

Immunomodulatory effects of intravenous BIS-1 F(ab')2 administration in renal cell cancer patients.
por: Janssen, R. A., et al.
Publicado: (1995)

FOXO1 inactivation induces cisplatin resistance in bladder cancer
por: Ide, Hiroki, et al.
Publicado: (2020)

The impact of adjuvant therapy on contralateral breast cancer risk and the prognostic significance of contralateral breast cancer: a population based study in the Netherlands
por: Schaapveld, Michael, et al.
Publicado: (2007)

The effects of vitamin E and selenium on cisplatin-induced nephrotoxicity in cancer patients treated with cisplatin-based chemotherapy: A randomized, placebo-controlled study
por: Nematbakhsh, Mehdi, et al.
Publicado: (2013)

Why choose the treatment with cisplatin for BRCA1 breast cancers patients?
por: Byrski, T, et al.
Publicado: (2012)

Gender Difference in Cisplatin-Induced Nephrotoxicity in a Rat Model
por: EL-Arabey, Amr Ahmed
Publicado: (2015)

Reply: Oxytocin ameliorates cisplatin-induced nephrotoxicity in Wistar rats
por: Nasri, Hamid
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_f565rkqe77v6v2cninkfvpj25j